Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 16, 2021 - Issue
Submit an article Journal homepage
154
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Long-Acting Bronchodilator Use in Chronic Obstructive Pulmonary Disease in Primary Care in New Zealand: A Retrospective Study of Treatment Patterns and Evolution Using the HealthStat Database

Dominique Milea1 Value Evidence and Outcomes, GlaxoSmithKline plc., Greater China and Intercontinental, 139234, SingaporeCorrespondence[email protected]
View further author information
,
See-Hwee Yeo1 Value Evidence and Outcomes, GlaxoSmithKline plc., Greater China and Intercontinental, 139234, SingaporeView further author information
,
Yein Nam2 Real World Evidence & Epidemiology, Adelphi Real World, Macclesfield, Cheshire, UKView further author information
,
Aldo Amador Navarro Rojas1 Value Evidence and Outcomes, GlaxoSmithKline plc., Greater China and Intercontinental, 139234, SingaporeView further author information
,
Sumitra Shantakumar1 Value Evidence and Outcomes, GlaxoSmithKline plc., Greater China and Intercontinental, 139234, SingaporeView further author information
,
Janine Beale3 Medical Affairs, GlaxoSmithKline plc., Auckland, New ZealandView further author information
,
Brett Marett3 Medical Affairs, GlaxoSmithKline plc., Auckland, New ZealandView further author information
,
Robert P Young4 Faculty of Medical and Health Sciences, University of Auckland, Auckland, New ZealandView further author information
,
Raewyn J Scott4 Faculty of Medical and Health Sciences, University of Auckland, Auckland, New ZealandView further author information
&
Barry Gribben5 Public Sector Surveying, CBG Health Research Limited, Auckland, New ZealandView further author information
 show all
Pages 1075-1091 | Published online: 20 Apr 2021

Figures & data

Figure 1 Study design, showing the observation and index periods for the main cohort of all LABD users (A); the sub-cohort of new LABD users (B); and the additional analysis of yearly rates of LABD initiation (C).

Notes: The timeline depicted is not to scale. The schematic shows an example index date, ie, the first prescription for an LABD during the index period, with the associated baseline period (≥12 months) shown preceding this (for all LABD users) and the relevant follow-up period (24 months), for new LABD users only, subsequently.
Abbreviation: LABD, long-acting bronchodilator.
Figure 1 Study design, showing the observation and index periods for the main cohort of all LABD users (A); the sub-cohort of new LABD users (B); and the additional analysis of yearly rates of LABD initiation (C).

Table 1 Baseline Characteristics of All LABD Users, Stratified by Type of LABD Treatment

Figure 2 Patient disposition for all LABD users.

Abbreviations: COPD, chronic obstructive pulmonary disease; LABD, long-acting bronchodilator.
Figure 2 Patient disposition for all LABD users.

Figure 3 LABD treatment for all LABD users, stratified by patient age at index (A) and ethnicity (B).

Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LABD, long-acting bronchodilator; LAMA, long-acting muscarinic antagonist.
Figure 3 LABD treatment for all LABD users, stratified by patient age at index (A) and ethnicity (B).

Figure 4 Patient exacerbation history at index for all LABD users, stratified by type of LABD treatment.

Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LABD, long-acting bronchodilator; LAMA, long-acting muscarinic antagonist.
Figure 4 Patient exacerbation history at index for all LABD users, stratified by type of LABD treatment.

Table 2 Baseline Characteristics of New LABD Users, Stratified by Type of LABD Treatment

Figure 5 LABD treatment in new LABD users, stratified by patient age at index.

Note: aLABA monotherapy, open triple therapy with LAMA+LABA+ICS, LAMA/LABA, or LAMA+ICS.
Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LABD, long-acting bronchodilator; LAMA, long-acting muscarinic antagonist.
Figure 5 LABD treatment in new LABD users, stratified by patient age at index.

Table 3 Time to and Type of Treatment Modifications Over 12 and 24 Months in New LABD Users

Figure 6 Yearly rates of LABD initiation from 2015 to 2017.

Notes: Patients could have had multiple concurrent prescriptions for LABD, eg, for a LAMA and for a LAMA/LABA combination therapy. aLAMA monotherapy or LAMA+LABA combination therapy in two inhalers, including tiotropium. bLAMA monotherapy, including tiotropium. cLAMA/LABA combination therapy in one inhaler; includes glycopyrronium+indacterol, tiotropium+olodaterol, and umeclidinium+vilanterol.
Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LABD, long-acting bronchodilator; LAMA, long-acting muscarinic antagonist.
Figure 6 Yearly rates of LABD initiation from 2015 to 2017.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.